{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:13:08Z","timestamp":1788480788251,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    The heterogeneity of multiple myeloma (MM) significantly impacts treatment outcomes. Myeloma risk profile (MRP), introduced by the UK Myeloma Research Alliance, is a novel prognostic model for patients with transplant\u2010ineligible newly diagnosed MM (TIE\u2010NDMM) utilizing easily available clinical parameters. In this study, we evaluated the prognostic value of MRP in TIE\u2010NDMM patients treated with novel agents. We retrospectively analysed the data of 799 evaluable MM patients diagnosed between January 2011 and January 2023, extracted from the Japan Clinical Hematology Research Group\u2010EAST (J\u2010CHARGE)\u2010MM database. Overall survival (OS) differed significantly across the three MRP risk groups (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). The MRP risk groups remained independently prognostic when adjusted for treatment period and first\u2010line therapy (medium vs. low: hazard ratio [HR], 1.71;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01; high vs. low: HR, 2.61;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). In subgroup analyses, the MRP classification significantly predicted OS in patients treated with bortezomib\u2010based and lenalidomide\u2010based regimens. However, there was no difference in OS between the MRP risk groups in patients treated with daratumumab\u2010based regimens. MRP is a robust prognostic tool for real\u2010world TIE\u2010NDMM patients treated with novel agents. Further studies are warranted to clarify its prognostic utility in the era of front\u2010line anti\u2010CD38 monoclonal antibody\u2010based therapies.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70810","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:40:26Z","timestamp":1788478826000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the\n                    <scp>UK<\/scp>\n                    Myeloma Research Alliance risk profile in transplant\u2010ineligible multiple myeloma patients treated with novel agents"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5340-6923","authenticated-orcid":false,"given":"Hitomi","family":"Nakayama","sequence":"first","affiliation":[{"name":"Department of Hematology Yokohama Municipal Citizen's Hospital  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3579-4018","authenticated-orcid":false,"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokohama Municipal Citizen's Hospital  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7524-9339","authenticated-orcid":false,"given":"Atsushi","family":"Takahata","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokosuka Kyosai Hospital  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4159-2834","authenticated-orcid":false,"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Hematology Juntendo University Nerima Hospital  Nerima City Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Hematology Ome Medical Center  \u014cme Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5196-3152","authenticated-orcid":false,"given":"Keigo","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Hematology Ome Medical Center  \u014cme Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1972-5095","authenticated-orcid":false,"given":"Takashi","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Hematology Niigata City General Hospital  Niigata Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1915-8997","authenticated-orcid":false,"given":"Toshiaki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology Teine Keijinkai Hospital  Sapporo Hokkaido Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-3429","authenticated-orcid":false,"given":"Kohtaro","family":"Toyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Fujioka General Hospital  Fujioka Gunma Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Senpuku","sequence":"additional","affiliation":[{"name":"Department of Hematology Ageo Central General Hospital  Ageo Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine Nihon University School of Medicine  Itabashi City Tokyo Japan"},{"name":"Department of Hematology Kasukabe Municipal Medical Center  Kasukabe Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Hematology Fukushima Medical University  Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2716-3377","authenticated-orcid":false,"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Science Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1955-074X","authenticated-orcid":false,"given":"Yuki","family":"Osada","sequence":"additional","affiliation":[{"name":"Department of Hematology Fraternity Memorial Hospital  Sumida City Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-3910","authenticated-orcid":false,"given":"Junichi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology TMG Asaka Medical Center  Asaka Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokohama City Minato Red Cross Hospital  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Saitama Cancer Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Oshikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology Japanese Red Cross Musashino Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japan Community Health Care Organization Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3780-5331","authenticated-orcid":false,"given":"Michihide","family":"Tokuhira","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japan Community Health Care Organization Saitama Medical Center  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology Fraternity Memorial Hospital  Sumida City Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-278X","authenticated-orcid":false,"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[{"name":"Department of Hematology Fukushima Medical University  Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-1988","authenticated-orcid":false,"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine Nihon University School of Medicine  Itabashi City Tokyo Japan"},{"name":"Department of Hematology and Rheumatology National Hospital Organization Saitama Hospital  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-3804","authenticated-orcid":false,"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine Nihon University School of Medicine  Itabashi City Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6850-4545","authenticated-orcid":false,"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Department of Hematology Ome Medical Center  \u014cme Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Toyota","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokosuka Kyosai Hospital  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-4760","authenticated-orcid":false,"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Hematology Institute of Science Tokyo  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"5","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as Main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas B","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah JJ","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","article-title":"Randomized clinical trial representativeness and outcomes in real\u2010world patients: comparison of 6 Hallmark randomized clinical trials of relapsed\/refractory multiple myeloma","volume":"20","author":"Chari A","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00277-018-3449-8","article-title":"Survival of non\u2010transplant patients with multiple myeloma in routine care differs from that in clinical trials\u2010data from the prospective German tumour registry lymphatic neoplasms","volume":"97","author":"Knauf W","year":"2018","journal-title":"Ann Hematol"},{"issue":"2","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the myeloma XI trial","volume":"34","author":"Pawlyn C","year":"2020","journal-title":"Leukemia"},{"issue":"31","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","DOI":"10.1126\/sageke.2005.31.pe24","article-title":"From bedside to bench: research agenda for frailty","volume":"2005","author":"Fried LP","year":"2005","journal-title":"Sci Aging Knowl Environ"},{"issue":"13","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo A","year":"2015","journal-title":"Blood"},{"issue":"1","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant\u2010ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM\u2010020) trial","volume":"34","author":"Facon T","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt M","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant\u2010ineligible patients with myeloma (UK myeloma research Alliance risk profile): a development and validation study","volume":"6","author":"Cook G","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bjh.16806","article-title":"Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population\u2010based study from the Danish national multiple myeloma registry","volume":"193","author":"Redder L","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262388","article-title":"Evaluation of the frailty characteristics and clinical outcomes according to the new frailty\u2010based outcome prediction model (myeloma risk profile\u2010MRP) in a UK real\u2010world cohort of elderly newly diagnosed myeloma patients","volume":"17","author":"Djebbari F","year":"2022","journal-title":"PLoS One"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2147\/OTT.S300834","article-title":"Evaluation of the UK myeloma research Alliance risk profile in Chinese patients with newly diagnosed multiple myeloma without autologous stem cell transplantation","volume":"14","author":"Ma K","year":"2021","journal-title":"Onco Targets Ther"},{"issue":"1","key":"e_1_2_12_15_1","article-title":"Multiple myeloma, version 5.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Kumar SK","year":"2026","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2010EMN evidence\u2010based guidelines for diagnosis, treatment and follow\u2010up of patients with multiple myeloma","volume":"22","author":"Dimopoulos MA","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12185-025-04069-y","article-title":"Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real\u2010world cohort using J\u2010CHAEGE\u2010MM database","volume":"123","author":"Tokuhira M","year":"2026","journal-title":"Int J Hematol"},{"issue":"3","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12185-025-04100-2","article-title":"Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J\u2010CHARGE study group","volume":"123","author":"Iriyama N","year":"2026","journal-title":"Int J Hematol"},{"issue":"26","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo A","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk\u2010stratification, and management","volume":"99","author":"Rajkumar SV","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy\u2010to\u2010use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda Y","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hon.3103","article-title":"Prognostic impact of the UK myeloma research Alliance risk profile in transplant\u2010ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: a supplementary analysis of JCOG1105","volume":"41","author":"Suzuki T","year":"2023","journal-title":"Hematol Oncol"},{"issue":"24","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International myeloma society\/international myeloma working group consensus recommendations on the definition of high\u2010risk multiple myeloma","volume":"43","author":"Avet\u2010Loiseau H","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70810","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70810","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:40:35Z","timestamp":1788478835000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":24,"alternative-id":["10.1111\/bjh.70810"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70810","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"2026-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjh.70810"}}